[Essential phospholipids in combined therapy of chronic circulatory insufficiency].
Essential phospholipids (essentiale-forte) was used in combined therapy of 36 patients with pronounced circulatory insufficiency and hepatic dysfunction. A 4-6-week course of this treatment 6 weeks after its termination resulted in good subjective response, positive changes in hemodynamics, intrahepatic cholestasis, synthetic function of the liver and lipid metabolism. The drug was well tolerated.
Golochevskaia
V S
VS
Department of Internal Diseases Propedeutics, MMA of IM Sechenov.
Baranskaia
E K
EK
Trofimenko
I V
IV
Balakhonova
N P
NP
Burmakin
I A
IA
Kop'ev
V I
VI
Zadorozhnaia
O O
OO
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000975:Antioxidants; D002316:Cardiotonic Agents; D004232:Diuretics; D010713:Phosphatidylcholines; C011246:essential 303 forte
Essentsial'nye fosfolipidy v kompleksnoí terapii khronicheskoí nedostatochnosti krovoobrashchenia.